Mary Jo Laffler
Latest From Mary Jo Laffler
The company is getting more attention these days for its TIGIT inhibitor tiragolumab in combination with Tecentriq for 1L NSCLC, but a new 1L monotherapy indication for Tecentriq helps it compete against Keytruda.
The limitations of launching during the pandemic will make it difficult to capitalize on a short window between the approvals.
Cemiplimab was a latecomer to the PD-1/L1 class, but a Phase III success in lung cancer will bring it to the main stage for immuno-oncology.
US biotech expands 2017 collaboration with Alnylam and inks collaboration with WuXi. Plus deals involving AbbVie, Allergan, Amazon, Thermo Fisher, Qiagen, Boehringer Ingelheim, Trutino, Taiho, Arcus, Eisai, Fuji Yakuhin, Hikma, Glenmark, Hanmi, GC, Bayer, GW.
Research published in JAMA shows that the pharmaceutical industry outpaces other industries in the S&P 500 on several measures of profitability.
Mylan’s full year 2019 earnings report was its last as an independent company, so the focus was on the coming merger with Pfizer’s Upjohn and growth prospects for the new company, Viatris.